Clinical trial · Interventional
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients. Thereafter patients receive additional consolidation and reinduction cycles combined with rituximab. In parallel minimal residual disease is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on results of MRD evaluation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Acute Lymphocytic Leukemia | Adult Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (18)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adriamycin | Drug | — | UNRESOLVED |
| Asparaginase | Drug | Asparaginase | ALIAS |
| CNS irradiation | Procedure | — | UNRESOLVED |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| Dexamethasone / Prednisolone | Drug | — | UNRESOLVED |
| G-CSF | Drug | — | UNRESOLVED |
| Mediastinal irradiation (if residual TU) |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Remission rate (cytologic, Remission rate (molecular), Remission duration, Disease free survival, Overall survival
Secondary outcomes (1)
- measure
- Dose and time compliance, Toxicity according to WHO, Death in induction and CR, Course of MRD
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * B-precursor ALL (common / pre B-ALL) * Standard risk * CD20 expression \>20% * Ph/BCR-ABL negative * Age 15-65 years (55-65 if biologically younger) * Written informed consent Exclusion Criteria: * Severe complications due to leukemia or secondary illnesses * Late relapse of childhood ALL * Cytostatic pretreatment * Pregnancy * Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent * Known severe allergy to foreign proteins
References
Publications (0)
Data not yet available